Stay updated with breaking news from Akro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report)’s share price rose 5.5% on Monday . The stock traded as high as $20.77 and last traded at $20.74. Approximately 65,585 shares changed hands during trading, a decline of 94% from the average daily volume of 1,191,632 shares. The stock had previously closed at $19.66. Analysts Set […]
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) COO Jonathan Young sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $20.15, for a total transaction of $100,750.00. Following the completion of the sale, the chief operating officer now owns 258,306 shares […]
Clough Capital Partners L P bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the third quarter, Holdings Channel.com reports. The institutional investor bought 72,200 shares of the company’s stock, valued at approximately $3,652,000. A number of other hedge funds and other institutional investors also recently bought and sold […]
New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) insider Catriona Yale sold 597 shares of the firm’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $20.76, for a total value of $12,393.72. Following the sale, the insider now owns 77,910 shares of the company’s stock, valued […]
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 7,405 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $20.02, for a total value of $148,248.10. Following the transaction, the chief executive officer now owns 552,539 shares of the […]
Commodore Capital LP boosted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 112.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,675,000 shares of the company’s stock after acquiring an additional 885,000 shares during the quarter. Akero Therapeutics accounts […]
Commodore Capital LP increased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 112.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,675,000 shares of the company’s stock after purchasing an additional 885,000 shares during the quarter. Akero Therapeutics comprises approximately 8.8% of Commodore Capital LP’s portfolio, making the stock […]
Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 19.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 26,819 shares of the company’s stock after purchasing an additional 4,332 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero […]
Swiss National Bank boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 46.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 96,300 shares of the company’s stock after buying an additional 30,700 shares during the period. Swiss National Bank’s holdings in Akero Therapeutics were worth $4,496,000 at the end […]